146 related articles for article (PubMed ID: 26015807)
41. [New techniques for optimization of thiopurine therapy in leukemia and transplantation].
Loennechen T; Lysaa RA; Giverhaug T; Sylte I; Mathiesen LE; Aarbakke J
Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1107-10. PubMed ID: 12043054
[TBL] [Abstract][Full Text] [Related]
42. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
[TBL] [Abstract][Full Text] [Related]
43. Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
Park SK; Hong M; Ye BD; Kim KJ; Park SH; Yang DH; Hwang SW; Kwak MS; Lee HS; Song K; Yang SK
Scand J Gastroenterol; 2016; 51(6):684-91. PubMed ID: 26863601
[TBL] [Abstract][Full Text] [Related]
44. Determination of thiopurine S-methyltransferase (TPMT) activity by comparing various normalization factors: reference values for Estonian population using HPLC-UV assay.
Oselin K; Anier K; Tamm R; Kallassalu K; Mäeorg U
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Apr; 834(1-2):77-83. PubMed ID: 16517227
[TBL] [Abstract][Full Text] [Related]
45. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
46. A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia.
Bainer RO; Trendowski MR; Cheng C; Pei D; Yang W; Paugh SW; Goss KH; Skol AD; Pavlidis P; Pui CH; Gilliam TC; Evans WE; Onel K
Cancer Manag Res; 2017; 9():397-410. PubMed ID: 28979163
[TBL] [Abstract][Full Text] [Related]
47. PRPS2 mutations drive acute lymphoblastic leukemia relapse through influencing PRPS1/2 hexamer stability.
Song L; Li P; Sun H; Ding L; Wang J; Li B; Zhou BS; Feng H; Li Y
Blood Sci; 2023 Jan; 5(1):39-50. PubMed ID: 36742181
[TBL] [Abstract][Full Text] [Related]
48. Towards personalized chemotherapy of acute lymphoblastic leukemia.
Hnízda A; Yang T
Oncotarget; 2018 Dec; 9(95):36728-36729. PubMed ID: 30613359
[No Abstract] [Full Text] [Related]
49. Monitoring and management of toxicities in long-term thiopurine therapy.
Keyashian K
Gastroenterol Hepatol (N Y); 2013 Oct; 9(10):672-4. PubMed ID: 24764783
[No Abstract] [Full Text] [Related]
50. Mismatch repair deficiency predicts benefit of anti-PD-1 therapy.
Lau E
Lancet Oncol; 2015 Jul; 16(7):e319. PubMed ID: 26062774
[No Abstract] [Full Text] [Related]
51. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
[TBL] [Abstract][Full Text] [Related]
52. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.
Graham RP; Kerr SE; Butz ML; Thibodeau SN; Halling KC; Smyrk TC; Dina MA; Waugh VM; Rumilla KM
Am J Surg Pathol; 2015 Oct; 39(10):1370-6. PubMed ID: 26099011
[TBL] [Abstract][Full Text] [Related]
53. The Ins and Outs of Small GTPase Rac1 in the Vasculature.
Marinković G; Heemskerk N; van Buul JD; de Waard V
J Pharmacol Exp Ther; 2015 Aug; 354(2):91-102. PubMed ID: 26036474
[TBL] [Abstract][Full Text] [Related]
54. Differential Expression of Cell Cycle Regulators During Hyperplastic and Hypertrophic Growth of Broiler Subcutaneous Adipose Tissue.
Zhang J; Suh Y; Choi YM; Chen PR; Davis ME; Lee K
Lipids; 2015 Oct; 50(10):965-76. PubMed ID: 26017028
[TBL] [Abstract][Full Text] [Related]
55. NOG1 downregulates type I interferon production by targeting phosphorylated interferon regulatory factor 3.
Xue Q; Zhu Z; Xue Z; Yang F; Cao W; Liu X; Liu H; Zheng H
PLoS Pathog; 2023 Jul; 19(7):e1011511. PubMed ID: 37410776
[TBL] [Abstract][Full Text] [Related]
56. New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
Weeramange C; Lansakara A; Dallman J; Nguyen T; Hulangamuwa W; Rafferty RJ
Medchemcomm; 2019 May; 10(5):717-725. PubMed ID: 31191862
[TBL] [Abstract][Full Text] [Related]
57. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Steeghs EMP; Boer JM; Hoogkamer AQ; Boeree A; de Haas V; de Groot-Kruseman HA; Horstmann MA; Escherich G; Pieters R; den Boer ML
Sci Rep; 2019 Mar; 9(1):4634. PubMed ID: 30874617
[TBL] [Abstract][Full Text] [Related]
58. Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
Torres Hernandez AX; Weeramange CJ; Desman P; Fatino A; Haney O; Rafferty RJ
Medchemcomm; 2019 Jan; 10(1):169-179. PubMed ID: 30774864
[TBL] [Abstract][Full Text] [Related]
59. Thiopurine methyltransferase activity in children with acute myeloid leukemia.
Sobiak J; Skalska-Sadowska J; Chrzanowska M; Resztak M; Kołtan S; Wysocki M; Wachowiak J
Oncol Lett; 2018 Oct; 16(4):4699-4706. PubMed ID: 30214603
[TBL] [Abstract][Full Text] [Related]
60. 6-mercaptopurine promotes energetic failure in proliferating T cells.
Fernández-Ramos AA; Marchetti-Laurent C; Poindessous V; Antonio S; Laurent-Puig P; Bortoli S; Loriot MA; Pallet N
Oncotarget; 2017 Jun; 8(26):43048-43060. PubMed ID: 28574837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
